Bank of New York Mellon’s Serina Therapeutics SER Stock Holding History

Bank of New York Mellon’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,739	Closed	-$57K	–	4163
2020 Q1	$57K	Hold	1,739	–	–	﹤0.01%	3957
2019 Q4	$111K	Buy	1,739 +94	+6%	+$5.08K	﹤0.01%	4011
2019 Q3	$114K	Sell	1,645 -138	-8%	-$13.1K	﹤0.01%	4004
2019 Q2	$230K	Buy	1,783 +497	+39%	+$67.3K	﹤0.01%	3881
2019 Q1	$183K	Sell	1,286 -21	-2%	-$3.07K	﹤0.01%	3905
2018 Q4	$137K	Buy	+1,307	New	+$166K	﹤0.01%	3918

Other funds holding SER

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Bank of New York Mellon's SER Position: Q2 2020 in Review

Bank of New York Mellon sold out of Serina Therapeutics (SER) in Q2 2020, closing a stake of 1,739 shares — an estimated $57K sold.

Bank of New York Mellon first reported a position in SER in Q4 2018 and held it in 6 quarters. The position peaked at $230K in Q2 2019. 48 funds tracked by Wall St. Rank hold SER as of Q2 2020.

Bank of New York Mellon reported no remaining Serina Therapeutics position as of Q2 2020 after selling out during the quarter.
Bank of New York Mellon sold 1,739 Serina Therapeutics shares in Q2 2020, an estimated $57K.
Bank of New York Mellon first reported a position in Serina Therapeutics in Q4 2018 and held it in 6 quarters.
Bank of New York Mellon's Serina Therapeutics position peaked at $230K in Q2 2019.
48 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2020.

Based on Bank of New York Mellon's 13F filing for Q2 2020, filed 12 Aug 2020.